The first triple GIP/GLP-1/Glucagon agonist. Phase 2 trials produced 24.2% mean body weight loss in 48 weeks — the greatest pharmacological weight loss ever recorded. Research-grade from QSC Peptides — USA, EU, UK, AU & CA domestic.
Over one billion people worldwide are living with obesity. It drives Type 2 diabetes, heart disease, fatty liver disease, sleep apnea, and certain cancers. Despite decades of effort, no pharmacological solution has come close to matching bariatric surgery outcomes — until Retatrutide.
Orlistat achieved ~5%. Phentermine ~9%. Semaglutide (Ozempic/Wegovy) changed the game with ~15%. Tirzepatide (Mounjaro) pushed further to ~21%. Then Retatrutide arrived with 24.2% in 48 weeks — and still declining.
We are witnessing the most significant pharmacological advance in metabolic medicine in a generation. A weekly injection approaching bariatric surgery outcomes, without the surgery.
Retatrutide (Reta / LY3437943) is the world's first triple GIP/GLP-1/Glucagon receptor agonist. Where Ozempic targets 1 receptor and Mounjaro targets 2, Retatrutide fires all 3 simultaneously — producing synergistic effects no predecessor could achieve.
Published in the New England Journal of Medicine, June 2023: 24.2% mean body weight reduction in 48 weeks. Weight loss curve still declining at trial end. No plateau. A result that approached what bariatric surgery had previously required invasive procedures to achieve.
Retatrutide holds the world record for pharmacological weight loss — 24.2% in 48 weeks. Still declining. No plateau reached.
Sources: NEJM 2023, SURMOUNT-1, STEP-1. Research reference only.
GIP receptor activation boosts glucose-dependent insulin secretion, reduces adipose tissue inflammation, and enhances fat cell sensitivity. Also present in tirzepatide — but Retatrutide goes two steps further.
The mechanism behind Ozempic. GLP-1 activation powerfully suppresses appetite via brain signals, slows gastric emptying to extend satiety, and improves post-meal glucose handling. The foundation of all modern weight-loss peptides.
The key differentiator. No other approved weight-loss drug targets glucagon receptors. This activation directly increases resting energy expenditure, accelerates lipolysis, and promotes thermogenesis — burning more calories at rest, not just eating less.
The simultaneous activation of all three receptor pathways produces synergistic effects — eating less AND burning more AND improving metabolic efficiency at once. This combination is why Retatrutide is categorically superior to every compound before it.
338 participants. 6 active dose arms. 48 weeks. The results were unlike anything seen in pharmaceutical research history.
Mean body weight. A 250 lb person loses ~60 lbs in 48 weeks. Weight loss still increasing at trial end — no plateau.
Mean waist circumference reduction. Visceral fat is metabolically more dangerous than subcutaneous fat — it wraps around organs and drives T2 diabetes, heart disease, and cancer risk.
Liver fat reduction — the strongest NASH/NAFLD result ever recorded from any pharmacological agent. Glucagon receptor activation drives direct hepatic fat mobilization.
Jastreboff AM et al., NEJM June 2023. Phase 2 trial, n=338. Research reference only.
Full Trial Analysis →From world-record weight loss to liver health, cardiovascular markers, joint disease, and brain health — Retatrutide's three-receptor mechanism touches every system obesity damages.
World-record pharmacological weight loss. 61 lbs lost by a 250 lb subject — approaching bariatric surgery territory without the knife.
Visceral fat is metabolically lethal. Reta directly reduces it — shrinking waist circumference by nearly 7 inches and slashing organ fat that drives diabetes, heart disease, and cancer.
The most powerful NASH/NAFLD result ever recorded. Glucagon receptor activation directly mobilizes hepatic fat — no GLP-1 only compound comes close to this liver health outcome.
Dual GIP+GLP-1 activation drives potent glucose-dependent insulin secretion — significant reductions in fasting glucose, fasting insulin, and HbA1c with direct T2 diabetes relevance.
Systolic BP −7 to −9 mmHg · Triglycerides ~−33% · LDL reduced · HDL improved. A full cardiometabolic benefit profile achieved simultaneously with weight loss.
The glucagon receptor addition is unique. It actively increases resting energy expenditure and thermogenesis — your body burns more calories at rest, not just eating fewer. No prior weight-loss drug does this.
Semaglutide plateaus by week 60. Tirzepatide plateaus by week 64. Retatrutide's curve was still declining steeply at trial end. If Phase 3 runs to 96 weeks, projections suggest 30%+ mean weight loss.
GLP-1 reduces intake. GIP improves insulin efficiency. Glucagon accelerates fat burning. Three simultaneous pathways produce synergistic, not additive, effects — explaining why 24.2% obliterates 14.9% + 20.9%.
C20 fatty acid conjugation extends half-life to ~7 days via albumin binding — enabling once-weekly subcutaneous injection that maintains consistent tri-receptor activation throughout the research timeline.
A significant portion of Phase 2 participants with sleep apnea showed improvement as neck and thoracic fat reduced. Weight-related sleep disorders are now an active Retatrutide research area.
Every 10 lbs of body weight equals ~40 lbs of pressure on knee joints. Retatrutide-mediated 60 lb weight loss translates to ~240 lbs of reduced joint force — with enormous implications for osteoarthritis research.
GLP-1 receptors are expressed throughout the brain. Early preclinical research suggests GLP-1 agonists may protect against neurodegeneration — Retatrutide's triple mechanism creates a uniquely powerful tool for brain-metabolism research.
Trial begins. Dose escalation starts at 1–2 mg/week.
Significant early weight loss as dose escalates toward 8–12 mg. GI adaptation underway.
End of dose escalation. Full 12 mg maintenance dose achieved. Weight loss accelerating.
Ongoing steady loss. Metabolic improvements compound — BP, triglycerides, liver fat all improving simultaneously.
Trial end. Still declining — no plateau. Curve trajectory suggests 30%+ at 72 weeks in Phase 3.
Obesity is not a willpower problem. It is a metabolic disease driven by hormones, genetics, and a food environment that outpaces our biology. For decades, medicine had no answer that worked. Then GLP-1 agonists arrived — and now Retatrutide is pointing toward a future where obesity is truly treatable.
Obesity drives 13 types of cancer, the majority of T2 diabetes cases, most heart failure, and severe sleep apnea. It is the most prevalent preventable disease in human history.
For decades, the best pharmacological obesity treatment achieved 5–10% weight loss — insufficient to meaningfully reduce disease burden. The GLP-1 revolution changed this. Retatrutide may complete it.
At this level of weight loss, T2 diabetes enters remission in most patients. Sleep apnea resolves. Cardiovascular risk drops dramatically. Joint disease halts. Retatrutide doesn't just treat obesity — it effectively treats every disease obesity causes.
The Phase 2 curve was still declining at 48 weeks. Phase 3 trials run 72–96 weeks at full dose. If the trajectory holds, Retatrutide could achieve mean weight loss that exceeds bariatric surgery — without the operation.
From browser to doorstep. The entire process takes under 5 minutes. Retatrutide ships from the domestic warehouse nearest you.
Fulfilled by QSC Peptides — ≥99% purity, COA on every order, free shipping. 9 concentrations · 10 and 20-vial kits · Domestic in 5 countries.
Genuine physical inventory in 5 countries. No customs risk. No international delays. What other suppliers label "domestic" — QSC actually is.
Every batch HPLC-tested. COA on every order. No exceptions. No batches below standard.
Real physical inventory in 5 countries. Not international shipments with a domestic address.
5mg to 100mg in both 10 and 20-vial kits — more options than any other domestic Retatrutide supplier.
Zero shipping on all orders. No minimums. No surprises at checkout. Free worldwide.
From $0.76/mg on bulk kits — up to 78% cheaper than major competitors. See full comparison →
Proprietary tracking — USPS, FedEx, and international carriers. Every order trackable from warehouse to door.
Start here. Plain-English guide to what Reta is, how it works, trial results, vs Ozempic and Mounjaro.
Start Here →All 6 dose cohorts, all endpoints, trajectory analysis, and Phase 3 status.
Read Analysis →Historical context, body composition breakdown, the no-plateau finding, and Phase 3 projections.
Read →Side-by-side: QSC vs Peptide Partners, PureRawz, KiloBio. Per-mg costs, shipping, COA. QSC wins.
Compare →Triple vs single GLP-1. Trial data, mechanism differences, why the third receptor changes everything.
Compare →Both activate GIP + GLP-1. Only Reta adds glucagon. That one receptor is the entire story.
Compare →Purity, warehouse selection, dosage sizing, red flags — everything before your first purchase.
Read Guide →What to look for, reconstitution protocol, storage, and red flags revealing inferior products.
Quality Guide →HPLC, mass spectrometry, COA verification, fake COA red flags, and independent testing services.
Testing Guide →Never used Bitcoin or USDT? 6-step guide from wallet setup to completing your QSC order.
Crypto Guide →Full product overview — all SKUs, pricing, COA process, domestic warehouses, and why QSC is the trusted choice.
Learn More →GLP-1, GIP, glucagon, HPLC, COA, lyophilization, dose escalation, NASH — 25+ terms defined.
View Glossary →TRIUMPH program explained. Expected Phase 3 weight loss (30%+?), FDA approval timeline 2027–28, what researchers can do now.
Phase 3 Guide →Definitive triple comparison — every metric, every receptor, every outcome. Side-by-side tables, weight loss visuals, research use case guide.
Full Comparison →5 domestic warehouses · ≥99% purity · COA every order · Free shipping · From $0.76/mg · The world's most powerful triple-agonist.